ClinicalTrials.Veeva

Menu

The Effects of Restriction Pressure on Muscle Damage Responses to Blood Flow Restriction Exercise

U

University of Surrey

Status

Completed

Conditions

Muscle Strength
Muscle Soreness
Muscle Damage

Treatments

Other: Blood flow restriction at 40% limb occlusion pressure
Other: Blood flow restriction at 80% limb occlusion pressure

Study type

Interventional

Funder types

Other

Identifiers

NCT05037942
FHMS 20-21 151 EGA

Details and patient eligibility

About

Blood flow restriction (BFR) exercise involves the application of a constriction device to the limbs to restrict muscle blood flow during exercise. In recent years, BFR has become increasingly popular due to its additive effects on low-load resistance training, often promoting greater increases in muscle strength and size compared to similar resistance training without BFR. However, like other exercise, it is possible that BFR exercise can cause exercise-induced muscle damage (EIMD) that results in short-term reductions in muscle function and increased muscle soreness and swelling. One major variable that may influence the onset of EIMD is the restriction pressure used to restrict blood flow; however, the influence of restriction pressure on resistance EIMD is unclear.

The purpose of this study is to investigate effects of two different restriction pressures (low and high) on EIMD responses to a bout of low-load BFR resistance exercise in a sample of healthy, active adults. It is hypothesised that a higher restriction pressure will result in increased EIMD compared to a lower restriction pressure. To test this hypothesis, participants will perform a lower-body exercise protocol with and without BFR, and several markers of EIMD will be assessed before and immediately, 24, 48, and 72 hours after the exercise.

Full description

Following screening for the inclusion and exclusion criteria of the study, eligible participants will be fully informed of the study purposes and procedures and written consent will be acquired. During this study, participants will be randomly allocated into one of two experimental groups, with each group performing blood flow-restricted knee extension exercise with one leg and the same exercise protocol without BFR with the contralateral leg. Experimental groups will be differentiated by the tourniquet pressure used during the BFR condition. Several indirect markers of EIMD will be assessed at baseline and 24, 48, and 72 hours after the exercise bout. Additional neuromuscular assessments will be performed immediately post-exercise to provide insight into the fatiguability of the exercise protocol.

Participants will be required to attend the laboratory on five separate occasions: one visit for screening, assessment of limb occlusion pressure (i.e., the lowest pressure required to occlude blood flow to the limb), and familiarisation of the exercise protocol and neuromuscular assessments, one visit for completion of the exercise protocol and baseline/post-exercise tests, and three follow-up visits. All participants will be asked to refrain from alcohol and exercise from 24 hours prior to the exercise trial up to their final visit. The consumption of any pain-relieving medications (e.g., anti-inflammatory drugs) and undergoing of any muscle damage treatments (e.g., massage) will be prohibited throughout the study. To minimise the effects of pre-exercise feeding on the outcome measures, visits will be scheduled for the morning and participants will attend the lab following an overnight fast of a minimum of 10 hours, although water may be consumed ad libitum. All post-exercise measures will be collected at the same time of day ± 1 hours.

Enrollment

34 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Recreationally active (defined as performing ≥ 150 minutes of moderate-intensity or ≥ 75 minutes of vigorous-intensity exercise per week for the past 6 months)
  • Resistance-untrained (defined as performing less than 2 resistance exercise sessions per week for the past 6 months)

Exclusion criteria

  • Any history of cardiovascular (including hypertension [diastolic > 90 and/or systolic blood pressure > 140 mmHg] and peripheral arterial vascular disease), metabolic, respiratory (including severe asthma), haematological (including deep vein thrombosis and pulmonary embolism), neurological, gastrointestinal, kidney, liver, or musculoskeletal disease
  • Current or previous musculoskeletal injury that may be aggravated by exercise
  • Current smoker
  • Recently used prescribed anti-inflammatory medication within the previous 1 month
  • Self-reported or diagnosed menstrual irregularities within ≥ 3 months prior to recruitment
  • Currently pregnant

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

34 participants in 4 patient groups

Blood flow-restricted exercise at 40% limb occlusion pressure (BFR-40)
Experimental group
Description:
Participants in BFR-40 will perform a lower-body exercise protocol under BFR set to 40% of the participants' relative limb occlusion pressure.
Treatment:
Other: Blood flow restriction at 40% limb occlusion pressure
Blood flow-restricted exercise at 80% limb occlusion pressure (BFR-80)
Experimental group
Description:
Participants in BFR-80 will perform the same lower-body BFR exercise protocol as BFR-40; however, the occlusion pressure will be set to 80% of the participants' relative limb occlusion pressure.
Treatment:
Other: Blood flow restriction at 80% limb occlusion pressure
Control for BFR-40
No Intervention group
Description:
Participants randomised to BFR-40 will perform the same exercise protocol without BFR with the contralateral leg.
Control for BFR-80
No Intervention group
Description:
Participants randomised to BFR-80 will perform the same exercise protocol without BFR with the contralateral leg.

Trial contacts and locations

1

Loading...

Central trial contact

Julie Hunt; Kyle Gapper

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems